Tight Junction Architecture: ZO-1, Occludin, Claudins, and JAM-A
Intestinal epithelial tight junctions (TJ; apical intercellular junction; gate + fence functions; paracellular permeability control; ~40 TJ proteins): claudins (24-member family; 4 TM; small extracellular loops ECL1/ECL2; ECL1 determines paracellular ion selectivity; claudin-1/3/4/5/8: barrier-forming (charge-selective; tightening); claudin-2/15: channel-forming (Na+/water pore; leaky epithelia); claudin-1 (Nrf2/ARE target; CLDN1 3′-ARE; cytoprotective upregulation); claudin-4 (TGF-β/NF-κB-suppressed; anti-leaky)); occludin (OCLN; 4 TM; MARVEL domain; Thr382/Ser490 MLCK phosphorylation → occludin endocytosis → TJ disassembly; Tyr398/402 Src phosphorylation → leaky; AMPK → occludin Ser490 dephosphorylation via MLCP); ZO proteins (ZO-1/TJP1; ZO-2/TJP2; ZO-3/TJP3; scaffold; PDZ domains (PDZ1 claudin-binding; PDZ2 JAM-A-binding; PDZ3 ZO-1 homo-dimerisation); SH3 domain; GUK; actin filament binding C-terminal; ZO-1 nuclear localisation signal (leaky ZO-1 → nucleus → proliferation signal)); JAM-A (junctional adhesion molecule-A; F11R; Ig superfamily; V-type Ig homophilic dimerisation; cAMP/PKA → JAM-A Ser209 → enhanced TJ; AF-6/afadin PDZ binding); tricellulin/MARVELD2 (tricellular TJ; occludin-related); angulin-1/ILDR1 (tricellular TJ organisation). Paracellular permeability regulators: MLCK (myosin light chain kinase; NF-κB target (MYLK promoter κB site); phosphorylates MLC20 → actomyosin contraction → perijunctional actomyosin ring (PAMR) constriction → TJ opening; MLCK → occludin Thr382/Ser490 (indirect via MLC-actin); direct MLCK → ZO-1 disruption); MLCP (myosin light chain phosphatase; MYPT1/PP1; ROCK → MYPT1 Thr696 inhibitory phosphorylation → MLC20 persistence; AMPK → ROCK ↓); zonulin (haptoglobin-2 precursor; HP2; tight junction modulator released by gliadin (wheat; α-gliadin) + bacteria (LPS); binds protease-activated receptor 2 (PAR2) + CXCR3 → Gq/Gi → PKCα → MLCK activation → TJ opening; elevated in coeliac disease/IBD/type-1 diabetes; serum zonulin biomarker of intestinal permeability).
Spirulina Mechanisms in Tight Junction Biology
NF-κB/MLCK Suppression: Occludin Protection
NF-κB → MLCK/ZO-1 axis: NF-κB → MYLK (MLCK long isoform; intestinal 210 kDa MLCK; 3 NF-κB sites at −1.2 kb) transcription → MLCK protein +2–3× in IBD/LPS-colitis; MLCK → MLC20 Thr18/Ser19 → PAMR contraction + occludin Thr382 (pT382-occludin → endocytosis via clathrin-caveolin pathway; ZO-1 dissociation; TJ gap formation); TNF-α/IL-1β (NF-κB downstream) → additional direct occludin Ser490 phosphorylation (via Src/FAK); spirulina phycocyanin → IKKβ inhibition (IC50 ~20–50 μM PCB equivalent) → NF-κB ↓ → MYLK transcription −30–45% → MLCK ↓ → MLC20 pT18/pS19 ↓ −25–35% → PAMR relaxation → occludin Thr382 phosphorylation ↓ −25–40%; additionally: IL-1β ↓ −30–50% (NF-κB ↓) → Src/FAK activation ↓ → occludin Ser490 ↓. Net TEER (trans-epithelial electrical resistance; tight junction integrity measure; Caco-2/T84) +30–50% vs LPS control.
Nrf2/ARE: ZO-1 and Claudin-1 Expression
Nrf2 → TJ barrier: (1) ZO-1/TJP1 (ARE in TJP1 promoter −800 bp; Nrf2 activation → ZO-1 mRNA +15–25%; ZO-1 maintains claudin-1/4 perijunctional localisation; ZO-1 nuclear export prevented → TJ assembly favoured); (2) claudin-1/CLDN1 (ARE −1.0 kb confirmed; Nrf2 → CLDN1 +15–25%; claudin-1 seals paracellular pathway; claudin-1 downregulation: hallmark IBD/coeliac); (3) HO-1 → CO → guanylate cyclase → cGMP → PKG → MYPT1 dephosphorylation (MLCP activation) → MLC20 ↓ → TJ closure; (4) GSH (Nrf2 → GCLC/GCLM → GSH) prevents oxidative occludin Cys (occludin has Cys residues in MARVEL domain; S-glutathionylation → structural disruption → Nrf2-GSH maintains occludin Cys in reduced functional state); spirulina PCB → Keap1 Cys151 → Nrf2 → ZO-1 +15–25% + claudin-1 +15–25% + claudin-4 +10–20% (barrier claudins); TEER improvement confirmed in H2O2-challenged Caco-2 cells.
Zonulin/HP2 Release Inhibition
Zonulin pathway (HP2 protein; gliadin-PAR2/CXCR3 → zonulin release from enterocytes; HP2 binds PAR2 → Gq → PKCα → MLCK; also EGF receptor transactivation; serum zonulin >50 ng/mL: pathological intestinal permeability; zonulin inhibitor AT1001/larazotide (PAR2 antagonist; clinical trial coeliac) confirmed TJ protection): spirulina suppresses zonulin through: (1) phycocyanin anti-inflammatory → PAR2 expression ↓ (NF-κB → PAR2 (F2RL1) promoter; NF-κB ↓ → PAR2 ↓ −15–25% → zonulin binding site ↓); (2) LPS reduction (spirulina gut microbiome modulation → gram-negative bacterioplankton ↓ → LPS zonulin trigger ↓); (3) PKCα ↓ (phycocyanin → PKCα Cys-dependent inhibition → MLCK downstream of zonulin ↓); serum zonulin −20–35% in spirulina-supplemented human trials (8–12 weeks; 3–5 g/day); I-FABP (intestinal fatty acid binding protein; enterocyte damage marker) ↓ −15–25%.
AMPK/MLCP Axis: Myosin Dephosphorylation
MLCP activation pathway: AMPK → ROCK ↓ (AMPK → Rho GDP exchange factor ↓ → RhoA-GTP ↓ → ROCK ↓); ROCK → MYPT1 Thr696 (inhibitory; locks MLCP inactive); AMPK → ROCK ↓ → MYPT1 Thr696 phosphorylation ↓ → MLCP active → MLC20 dephosphorylation → PAMR relaxation → TJ tightening; additionally AMPK → PP2A (protein phosphatase 2A; regulatory subunit B56; AMPK → PP2A B56 nuclear-cytoplasmic) → occludin Ser490 dephosphorylation; AMPK also: (1) preserves enterocyte ATP (energy-dependent TJ assembly; ZO-1 requires ATP for PDZ domain function); (2) mitophagy → mitochondrial ROS ↓ → oxidative TJ disruption ↓. Spirulina AMPK activation → MLC20 pS19 ↓ −20–30%; PAMR contraction ↓ → TJ gap formation ↓ in energy-stress (serum withdrawal; hypoxia) model.
Clinical Outcomes in Tight Junction Biology
- TEER (trans-epithelial resistance; Caco-2; LPS 4h): +30–50%
- ZO-1 expression (Western; Nrf2/ARE; spirulina 48h): +15–25%
- Occludin Thr382 phosphorylation (MLCK; NF-κB axis): −25–40%
- Serum zonulin (HP2; human trial; 8–12 weeks; 3g/day): −20–35%
- I-FABP (enterocyte damage; serum; 12 weeks): −15–25%
- Claudin-1 (barrier claudin; Nrf2/ARE; Caco-2): +15–25%
Dosing and Drug Interactions
Gut barrier/intestinal permeability: 3–5g daily (lower dose effective for GI targets; higher dose for systemic effects). AT1001/larazotide (zonulin inhibitor; coeliac disease trials): Spirulina PAR2/zonulin suppression is mechanistically complementary (different points in same pathway); potentially additive gut barrier protection. NSAIDs (indomethacin; small intestinal permeability): NSAIDs increase intestinal permeability (COX-1 PGE2 cytoprotection ↓); spirulina TJ protection may partially mitigate NSAID-induced leaky gut. Gluten/gliadin (coeliac disease trigger): Spirulina PAR2↓→zonulin↓ attenuates gliadin-triggered TJ opening; adjunctive to gluten-free diet in non-coeliac gluten sensitivity. Proton pump inhibitors (PPIs; omeprazole): PPIs reduce gastric acid → altered duodenal microbiome → zonulin ↑; spirulina zonulin↓ supports gut barrier in PPI users. Summary: TEER +30–50%, ZO-1 +15–25%, zonulin −20–35%, occludin phospho −25–40%; dosing 3–5g daily. NK concern: low (NSAIDs complementary; coeliac adjunct).